-
-
-
-
-
-
-
Stifel Downgrades Exact Sciences (EXAS) to Hold
-
-
-
-
-
-
-
UBS Reiterates Neutral Rating on Exact Sciences (EXAS) Following Abbott Deal Reports
-
-
-
-
-
-
-
Exact Sciences shares soar on report Abbott is nearing deal for the company
-
-
-
-
-
-
-
Exact Sciences acquires exclusive license for Freenome blood-based CRC tests
-
-
-
-
-
-
-
Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members
-
-
-
-
-
-
-
Exact Sciences Announces Second-Quarter 2023 Results
-
-
-
-
-
-
-
Exact Sciences Announces First Quarter 2022 Results
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

